Attributes | Values |
---|
rdf:type
| |
description
| - wetenschappelijk artikel (nl)
- article scientifique publié en 2020 (fr)
- artículu científicu espublizáu n'abril de 2020 (ast)
- наукова стаття, опублікована 15 квітня 2020 (uk)
- scientific article published on 15 April 2020 (en)
|
publication date
| |
publication date
| |
author name string
| |
author name string
| - Ayalew Tefferi
- Naseema Gangat
- Traci L Kruer
- Alan F List
- Aref Al-Kali
- Eric Padron
- Mrinal M Patnaik
- David A Sallman
- Rami S Komrokji
- Ted Shih
- Christopher Letson
- Abhishek Mangaonkar
- Darci Zblewski
- Maria E Balasis
- Adrian Lo
- Cameron Durrant
- Hannah Newman
- Jeffrey Hirvela
- Rachel Heuer
|
rdfs:label
| - Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML) (en)
- Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML) (nl)
|
skos:prefLabel
| - Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML) (en)
- Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML) (nl)
|
name
| - Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML) (en)
- Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML) (nl)
|
author
| |
author
| |
title
| |
title
| - Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia (CMML) (en)
|
instance of
| |
instance of
| |
main subject
| |
main subject
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
DOI
| |
DOI
| |
DOI
| |
PMCID
| |
PMCID
| |
is about
of | |
is cites work
of | |
is cites work
of | |